Description
HYALUAL Xela Rederm 1.1% 1x2ml is a sterile injectable skin revitalisation treatment developed by HYALUAL Institute. Classified as a skin booster and biorevitalisation product, Xela Rederm combines non-crosslinked hyaluronic acid with sodium succinate to support skin hydration and improve the appearance of ageing skin.
The Redermalization® concept utilised by HYALUAL combines the hydrating properties of hyaluronic acid with succinic acid (sodium succinate), a component involved in cellular metabolic processes. According to manufacturer documentation, the formulation is intended to improve skin quality, support hydration, and address visible signs associated with photoageing and age-related skin changes.
The 1.1% formulation contains 11 mg/ml hyaluronic acid and 16 mg/ml sodium succinate and is generally positioned as the lowest-concentration product within the Xela Rederm portfolio. It is intended for professional administration by appropriately trained healthcare practitioners.
What HYALUAL Xela Rederm 1.1% Is Similar To
HYALUAL Xela Rederm 1.1% belongs to the category of injectable skin boosters and biorevitalisation products designed to improve hydration and overall skin quality. It may be compared with products such as Profhilo®, Jalupro®, and other non-volumising skin rejuvenation injectables.
Like Profhilo®, Xela Rederm aims to improve skin quality rather than create significant volume augmentation. However, the two products differ in composition. Profhilo® is based on stabilised hyaluronic acid complexes, whereas Xela Rederm combines non-crosslinked hyaluronic acid with sodium succinate as part of the Redermalization® concept.
Compared with amino acid-based biorevitalisers such as Jalupro®, HYALUAL Xela Rederm focuses on the synergistic action of hyaluronic acid and succinate rather than amino acid supplementation. Clinical indications overlap in areas such as hydration support and improvement of skin appearance.
This comparison is provided for clinical orientation only and does not imply interchangeability.
Treatment Areas / Indications
According to manufacturer information, HYALUAL Xela Rederm 1.1% may be used in areas including:
- Face
- Neck
- Décolletage
- Hands
- Periorbital area
- Areas showing signs of dehydration
- Areas affected by photoageing
- Skin with reduced elasticity and tone
Treatment planning should always be determined by qualified healthcare professionals following patient assessment.
Usage / Administration (IFU-Only Section)
According to publicly available manufacturer guidance:
Injection depth: Intradermal administration.
Volume per injection site: Not provided by manufacturer.
Needle gauge: Not provided by manufacturer in publicly available IFU documentation.
Frequency / Number of sessions: Not provided by manufacturer.
Professional-use disclaimer: HYALUAL Xela Rederm 1.1% should only be administered by qualified medical professionals trained in aesthetic injection procedures and appropriate aseptic techniques.
Some practitioners utilise specific mesotherapy patterns and treatment protocols; these approaches are not included in the publicly available manufacturer IFU and should not be considered official administration guidance.
Ingredient List
Active Ingredients
- Non-crosslinked Hyaluronic Acid
- Sodium Succinate (Succinic Acid Salt)
Hyaluronic Acid Concentration
- 11 mg/ml (1.1%)
Sodium Succinate Concentration
- 16 mg/ml
Lidocaine Content
- No lidocaine reported by manufacturer.
Excipients
- Phosphate-buffered solution
- Water for injection
Additional excipient details are not comprehensively specified in publicly available documentation.
Presentation & Longevity
Presentation
- 1 × 2ml prefilled sterile syringe
- Single-use injectable product
- Professional-use packaging
Longevity
The manufacturer does not provide a universal duration of effect applicable to all patients. Treatment outcomes and persistence may vary depending on age, skin condition, treatment protocol, lifestyle factors, and practitioner assessment.[1]
Where longevity estimates are referenced by distributors or clinicians, these should be interpreted as observational information rather than manufacturer-guaranteed outcomes.
Safety Notes / Contraindications
According to manufacturer guidance and standard injectable skin booster precautions:
- Contraindicated in patients with known hypersensitivity to any component of the formulation.
- Should not be administered in areas with active infection, inflammation, or dermatological disease.
- Not recommended during acute systemic illness.
- Treatment should only be performed by appropriately qualified healthcare professionals.
Patients should undergo a full consultation and suitability assessment before treatment.
Regulatory Status
Manufacturer: HYALUAL Institute (Institute Hyalual GmbH).
Regulatory Status: CE-marked medical device according to manufacturer and distributor documentation.
Users should verify the latest regulatory classification, conformity marking, and market authorisation status directly through the manufacturer, packaging, or applicable regulatory databases.
FAQ
1. What is HYALUAL Xela Rederm 1.1% used for?
HYALUAL Xela Rederm 1.1% is an injectable skin revitalisation treatment designed to support skin hydration and improve overall skin quality. Manufacturer information indicates use in patients experiencing dehydration, reduced elasticity, and visible signs of skin ageing.
2. What is Redermalization®?
Redermalization® is the treatment concept developed by HYALUAL that combines non-crosslinked hyaluronic acid with sodium succinate. The approach aims to support hydration while incorporating succinate, a compound involved in cellular metabolic pathways.
3. Does HYALUAL Xela Rederm 1.1% contain lidocaine?
No. Public manufacturer documentation indicates that HYALUAL Xela Rederm 1.1% does not contain lidocaine. Practitioners seeking local anaesthetic-containing products should review alternative formulations where appropriate.
4. How is Xela Rederm different from dermal fillers?
Unlike traditional dermal fillers, Xela Rederm is not primarily intended for volume augmentation or contouring. Instead, it is designed to support skin quality and hydration through intradermal administration. The product therefore belongs to the skin booster category rather than the volumising filler category.
5. How does Xela Rederm compare with Profhilo®?
Both products are commonly categorised as skin quality treatments. However, Profhilo® relies on stabilised hyaluronic acid complexes, whereas Xela Rederm combines non-crosslinked hyaluronic acid with sodium succinate. The products differ in formulation technology and treatment philosophy despite overlapping clinical objectives.
